Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
<0.01Last Year’s EPS
0.03Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a generally constructive long-term story—double-digit revenue growth, strong adjusted EBITDA expansion, margin improvement, encouraging product-level performance (notably On-X and tissue processing), rapid deleveraging, and a strategic acquisition (Endospan/NEXUS) that completes a differentiated aortic arch portfolio. Near-term execution challenges—lower-than-expected AMDS starter-set conversions, regional softness (Middle East), targeted supply-chain constraints, and a moderated full-year guidance—tempered the immediate outlook. Management provided clear remediation plans (value analysis committee work, programs to reduce the upfront AMDS burden, inventory and hiring plans for NEXUS) and maintained multi-year pipeline catalysts (ARTISON, C-Branch LSA) that support future upside.Company Guidance
Quarterly Revenue Growth
Total revenues of $116.3 million in Q1 2026, up 12% year-over-year on a constant currency basis.
Strong Adjusted EBITDA and Margin Expansion
Adjusted EBITDA increased ~26% to $22.1 million (from $17.5 million), with adjusted EBITDA margin of 19%, an ~130 basis point improvement versus prior year.
Product Line Outperformance
Notable product growth in the quarter: On-X revenue +17% YoY (constant currency), tissue processing +23% YoY (normalization after 2024 cybersecurity event), stent grafts +10% YoY, while BioGlue was relatively flat.
Encouraging AMDS Implant and Reorder Patterns
While starter-set sales lagged, implant and reorder activity within accounts using AMDS exceeded expectations, supporting long-term adoption thesis and near-term ramp potential once remaining barriers are addressed.
Strategic Acquisition and Portfolio Expansion (Endospan / NEXUS)
Company exercised option to acquire Endospan following U.S. PMA approval of NEXUS (early April). NEXUS plus AMDS and C-Branch LSA will create a three-pronged aortic arch portfolio; U.S. commercial launch targeted for 01/01/2027. Total U.S. addressable market for both NEXUS cohorts estimated at ~$150 million (dissections ~$100 million).
Pipeline Progress and Future Market Opportunities
ARTISON IDE trial for next-generation frozen elephant trunk has 26 of 132 patients enrolled; full enrollment anticipated mid-2027. C-Branch LSA expected FDA approval around 2029, representing an incremental ~$80 million annual U.S. market opportunity.
Improved Balance Sheet Metrics
Net leverage ratio improved to 1.8x at 03/31/2026, down from 4.0x a year earlier. Cash of ~$55.8 million with $215.4 million debt (net of unamortized loan costs). Free cash flow negative $6.8 million in Q1 2026 versus negative $20.6 million prior-year quarter (seasonally low quarter but substantially improved).
DE:CYL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:CYL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €29.60 | €26.20 | -11.49% |
Feb 12, 2026 | €33.70 | €33.75 | +0.15% |
Nov 06, 2025 | €40.05 | €41.10 | +2.62% |
Aug 07, 2025 | €27.50 | €30.00 | +9.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Artivion Inc. (DE:CYL) report earnings?
Artivion Inc. (DE:CYL) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Artivion Inc. (DE:CYL) earnings time?
Artivion Inc. (DE:CYL) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Artivion Inc. stock?
The P/E ratio of Artivion is N/A.
What is DE:CYL EPS forecast?
DE:CYL EPS forecast for the fiscal quarter 2026 (Q2) is <0.01.